Atopic Dermatitis

Andrew Blauvelt, MD, MBA, shares highlights from his RAD session, "Battle of the Titans 2: Challenging Patient Cases: Who is Eligible for Systemic Treatment in Atopic Dermatitis?"

A recently presented poster session from RAD 2023 evaluated a gene expression based molecular test’s differential diagnosis of psoriasis and eczema.

Catch up on coverage from the first day of Revolutionizing Atopic Dermatitis.

The RAD conference provides the chance to take a deep dive into one specific disease state in a focused setting.

Let us know what content you want to see from RAD.

Results of a new study indicate that baricitinib offers a potential therapeutic option with a favorable benefit-risk profile for pediatric patients with moderate-to-severe AD.

Physical activity and exercise may lead to improved mental health but exacerbate skin conditions.

ASLAN Pharmaceuticals will present 2 late-breaking abstracts and 2 additional abstracts.

When compared to a vehicle control cream, researchers said delgocitinib cream proved more efficacious.

Click here to answer this week's poll.

Results of the phase 3 ECZTRA 6 trial found that the efficacy of the drug was maintained by more than 50% of patients at 52 weeks.

Researchers pooled evidence supporting the way these 2 factors correlate.

Researchers said emollients markedly reduced lesions and other atopic dermatitis-related factors.

Researchers said the drug is capable of restoring a healthy skin biome.

Block spoke to the founder of the Eczema Sample Store over Instagram Live to bring more awareness to the company’s mission.

The expected PDUFA date is December 16, 2023.

Researchers said occlusive materials used in gloves can lead to irritant contact dermatitis.

The Minghui Pharmaceutical study met both primary and all key secondary endpoints.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, summarize the TRuE-AD1 and TRuE AD2 phase 3 trial and provide take home messages topical ruxolitinib cream for the treatment of atopic dermatitis.

Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss take a closer look at the TRuE-AD1 and TRuE AD2 phase 3 trial and provide context regarding ruxolitinib cream for the treatment of atopic dermatitis in the clinical setting.

James Q Del Rosso, DO, takes a closer look at the trial data regarding timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis.

ADX‑629 also is being evaluated in Phase 2 clinical trials for the treatment of chronic cough, idiopathic nephrotic syndrome, and Sjögren-Larsson Syndrome.

The study suggests that treatments for allergic reactions could help decrease the risk of having joint problems.

Researchers say itch and inflammation markers were not met, and trial results are not conclusive.

James Q Del Rosso, DO, Raj Chovatiya, MD, PhD, Lisa Swanson, MD, discuss the week 8 change results of ruxolitinib cream from the TRuE-AD1 and TRuE AD2 phase 3 trial.